

I hereby certify that this correspondence is  
being deposited with the United States  
Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,  
Washington, D.C. 20231,

On August 20, 2002

Quine Intellectual Property Law Group, P.C.

By [Signature]  
Amelia Groth

TECH CENTER 1600/2800

AUG 26 2002

RECEIVED

#6  
KAY  
8-27-02  
attachment

Attorney Docket No. 407T-994110US  
Client Ref. No. 2000-388-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

William M. Partridge, *et al.*

Application No.: 10/005,996

Filed: December 3, 2001

For: ANTISENSE IMAGING OF GENE  
EXPRESSION OF THE BRAIN IN VIVO

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR § 1.97 and  
§ 1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the  
attention of the Examiner. Copies of the references are enclosed. It is respectfully requested  
that the cited information be expressly considered during the prosecution of this application,  
and the references be made of record therein and appear among the "references cited" on any  
patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tom Hunter', with a long horizontal flourish extending to the right.

Tom Hunter  
Reg. No. 38,498

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. Box 458  
Alameda, CA 94501  
Tel: (510) 337-7871  
Fax: (510) 337-7877

TH:ag

Please type a plus sign (+) inside this box → ☐

(Modified) PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)	Application Number	10/005,996
	Filing Date	December 3, 2001
	First Named Inventor	William M. Partridge
	Group Art Unit	1645
	Examiner Name	Unassigned
Total Number of Pages in This Submission	Attorney Docket Number	407T-994110US


1645  
+  
TECH CENTER 1600/2900  
AUG 9 6 2002

RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Cited References; receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<b>Authorization to Charge Deposit Account</b> Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group, P.C.
Signature	
Date	19 August 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: August 20, 2002			
Typed or printed name	Amelia Groth		
Signature		Date	August 20, 2002



Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/005,996
Filing Date	December 3, 2001
First Named Inventor	William M. Partridge
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	407T-994110US
Date Submitted	

RECEIVED  
AUG 26 2002  
TECH CENTER 1600/2000

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	01	4,801,575		Pardridge	01-31-1989	
	02	4,902,505		Pardridge et al.	02-20-1990	
	03	6,287,792	B1	Pardridge et al.	09-11-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	04	EP	0 592 564	B1				


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	05	Agrawal et al. (1991) <i>Proc. Natl. Acad. Sci., USA</i> , 88:7595-7599.	
	06	Boado and Pardridge (1994) <i>Bioconj. Chem.</i> , 6: 406-410	
	07	Boado and Pardridge (1998) <i>Mol. Brain Res.</i> 59: 109-113.	
	08	Boado et al. (1999) <i>Proc. Natl. Acad. Sci., USA</i> , 96: 12079-12084.	
	09	Boado et al. (2000) <i>J. Pharmacol. Exp. Ther.</i> , 295: 239-243.	
	10	Brown et al. (1994) <i>J. Biol. Chem.</i> , 269:26801-26805.	
	11	Chem et al. (1990) <i>Drug Metab. Dispos.</i> 18:518-818.	
	12	Chinnery et al. (1999) <i>Gene Ther.</i> 6: 1919-1928.	
	13	Coloma et al. (2000) <i>Pharm. Res.</i> 17:266-274.	
	14	Cossum et al. (1993) <i>J. Pharmacol. Exp. Ther.</i> , 267: 1181-1190.	
	15	Crookie (1993) <i>FASEB J.</i> 7:533-539.	
	16	de Smidt et al. (1991) <i>Nucleic Acids Res.</i> 19: 4695-4700.	
	17	Demidov et al. (1994) <i>Biochem. Pharmacol.</i> 48: 1310-1313.	
	18	Gee et al. (1998) <i>Antisense and Nucleic Acid Drug Develop.</i> 8:103-111.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number	10/005,996
	Filing Date	December 3, 2001
	First Named Inventor	William M. Partridge
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	407T-994110US
	Date Submitted	




RECEIVED  
AUG 28 2002  
TECH CENTER 1600/2900

19	Hanvey et al. (1992) Science., 258:1481-1486.	
20	Heffetz et al. (1989) Eur. J. Biochem. 182:343-348.	
21	Hnatowich (1999) J. Nucleic Med. 40: 693-703.	
22	Huwyler and Pardridge (1998) J. Neurochem. 70:883-886.	
23	Kang et al.(1995) Drug Metab. Dispos. 23: 55-59.	
24	Kirupa et al. (1999) Phil. Trans. R. Soc. Lond., 354: 963-969.	
25	Kobori et al. (1999) NeuroReport 10: 2971-2974.	
26	Krieg et al. (1993) Proc. Natl. Acad. Sci., USA, 90: 1048-1052.	
27	Kurihara and Pardridge (1999) Cancer Res. 54: 6159-6163.	
28	Kurihara et al. (1999) Bioconjugate Chem. 10: 502-511.	
29	Lee et al. (2000) J. Pharmacol. Exp Ther. 292:1048-1052.	
30	Li et al. (1999) Protein Engineering 12:787-796.	
31	Lockhart and Winzeler (2000) Nature., 405: 827-836	
32	Mash et al. (1990) J. Neurochem. 55: 1972-1979.	
33	Mayfield and Corey (1999) Anal. Biochem., 268: 401-404.	
34	Nielsen et al. (1994) Bioconjugate Chem. 5: 3-7.	
35	Pardridge (2001) Drug Discovery Today., 6: 104-106	
36	Pardridge (1997) J. Cereb. Blood Flow Metabol. 17:713-731.	
37	Pardridge et al. (1995) Pharm. Res. 12:807-816.	
38	Pardridge et al. (1995)Proc. Natl. Acad. Sci., USA, 92:5592-5596.	
39	Penichet et al. (1999) J. Immunol. 163:4421-4426.	
40	Rebert et al. (1990) Pharmacol. Biochem. Behav. 36: 351-356.	
41	Rockwell et al. (1997)Proc. Natl. Acad. Sci., USA, 94:6523-6528.	
42	Samii et al. (1994) Am. J. Physiol., 267: E124-E134.	
43	Shechter et al. (1982) Nature 216:542-545.	
44	Shi and Pardridge (2000) Proc. Natl. Acad. Sci., USA, 97, 7567-7572.	
45	Shi et al. (2000) Proc. Natl. Acad. Sci., USA, 97: 14709-14714.	
46	Skarlatos et al. (1995) Brain Res., 683: 164-171	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<div>Substitute for form 1449A-B/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>	Complete if Known	
	Application Number	10/005,996
	Filing Date	December 3, 2001
	First Named Inventor	William M. Partridge
	Group Art Unit	1645
	Examiner Name	Unassigned
	Attorney Docket Number	407T-994110US
	Date Submitted	

RECEIVED  
AUG 26 2002  
TECH CENTER 1600/2900

47	Stein and Cheng (1993) Science 261:1004-1012.	
48	Tavitian et al. (21998) Nat. Med., 4: 467-471	
49	Tsukamoto et al. (1997) J. Neurochem. 68: 2587-2592.	
50	Tyler et al. (1999) Proc. Natl. Acad. Sci., USA, 96: 7053-7058.	
51	Ueda et al. (1993) J. Neurochem. 60: 106-113.	
52	Whitesell et al. (1993) Proc. Natl. Acad. Sci., USA, 90: 4665-4669.	
53	Wickstrom (1986) J. Biochem. Biophys. Methods 13:97-102.	
54	Wittung et al. (1994) Nature 368:561-563.	
55	Wojcik et al. (1996) J. Pharmacol. Exp. Ther. 278:404-410.	
56	Wu et al. (1996) J. Pharmacol. Exp. Ther., 276: 206-211.	
57	Zendegui et al. (1992) Nucleic Acids Res. 20:307-314.	
58	Zhang and Pardridge (2001) J. Neurochem., 76: 1597-1600.	
59	Zhao et al. (1999) J. Biol. Chem. 274: 34893-34902.	
60	Zick et al. (1984) J. Biol. Chem. 259:4396-4400.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.